Authors: Sharon Salt, Editor
Take a look at our previous content mentioned in our video update here:
You might also like:
Pick of the posters
- Kappos L, Wolinsky JS, Giovannoni G et al. Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. These Phase III clinical trial data sets of patients with relapsing multiple sclerosis (MS) were used to further understand the relative contribution of RAW versus PIRA events to the overall accumulation of disability in patients with relapsing forms of MS treated with a highly efficacious (ocrelizumab) versus a platform injectable disease-modifying treatment (IFN β-1a). The researchers concluded that a considerable proportion of overall accumulation in disability in a typical relapsing MS population is independent of relapses and might be related to an underlying progressive course, thus challenging the current phenotypical distinction of relapsing and progressive forms of MS; also that MS may be seen as a disease continuum in which the extent of PIRA and RAW varies in more progressive versus more relapsing forms of MS; and finally ocrelizumab was shown to be superior to IFN β-1a in preventing both forms of confirmed accumulation of disability – either RAW events due to relapse with incomplete recovery or PIRA events that might represent an underlying progressive course.
- Veroni C, Marnetto F, Bertolotto A et al. Altered EBV transcriptional profile in the peripheral blood of CIS and MS patients. The aims of this study were to quantify EBV DNA and RNA in peripheral blood mononuclear cells from healthy donors and therapy-free patients with RRMS; and to analyze EBV transcripts in CSF cell samples matched to peripheral blood mononuclear cells from people with RRMS. According to the authors, this is the first study to show EBV RNA alterations in peripheral blood of persons with RRMS compared to healthy donors – strengthening the idea that defective control of EBV infection is associated with MS. The authors also noted that these data suggests that markers of EBV deregulation in the peripheral blood can be monitored during therapy and could provide useful information on the relationship between drug response and changes in EBV–immune system interaction.
- Uher T, Benova B, Kardnozkova L et al. Relationship between serum neurofilament light chain levels and cognitive decline over 9-years follow-up in patients after first demyelinating event suggestive of MS. The objective of this study was to investigate the relationship between early serum neurofilament levels and evolution of cognitive decline over 9 years. The authors concluded that: pathological serum neurofilament levels at disease onset were associated with verbal memory decline over long-term follow-up; similarly as in imaging studies, the association between para-clinical markers of disease activity and cognitive measures may be substantially stronger in more advanced disease stages; and studies on larger cohorts with higher disease burden are warranted.
- Marrie RA, Garland A, Schaffer A et al. Multiple sclerosis is associated with an increased risk of acute myocardial infarction. This study focused on examining the risk of incident acute myocardial infarction in the MS population as compared to a matched population without MS, controlling for traditional risk factors. Their study population included 14,565 cases with MS and 72,825 matched controls. Results of the study indicated that after age-standardization, incidents of acute myocardial infarction was higher in the MS than in the matched population (incidence rate ratio = 1.18; 95%CI: 1.03-1.36). The age at acute myocardial infarction onset was also earlier in those with MS than those without. After adjustment, the risk of acute myocardial infarction was higher in the MS versus the matched population.
Today at our booth
We’ve had a very busy morning of sign-ups today – thank you to everyone who came along to our booth and registered to become a member. We’re thrilled to welcome you to Neuro Central! If you haven’t had the chance to pop over then please do on Thursday or Friday and you could still be in the chance to win a prize from our booth. Alternatively, if you’re an early career researcher and are also in attendance, do let us know if you’d be interested in publishing a conference report for us. You can contact our Editor via email by clicking here.
Remember to sign up for Neuro Central, or follow our Twitter updates @Neuro_Central
Best of social media #ECTRIMS2018
RT shiftms: We caught up with Dr Tjalf Ziemssen ECTRIMS to talk about how the future of big data and what wearables mean to medicine. https://t.co/ZZCyFMCm6i
What do you guys think about the future of all this data?#ectrims2018
— Gavin Giovannoni (@GavinGiovannoni) October 10, 2018
— Rachel Farrell (@RFarrell_CNR) October 10, 2018